Valuation: Verastem, Inc.

Market Cap 504M 440M 407M 373M 707M 48.52B 719M 4.85B 1.91B 23.69B 1.89B 1.85B 81.8B P/E 2026 *
-3.62x
P/E 2027 * -5.11x
Enterprise Value 339M 296M 274M 251M 475M 32.62B 484M 3.26B 1.28B 15.93B 1.27B 1.24B 54.99B EV / Sales 2026 *
3.32x
EV / Sales 2027 * 1.65x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-0.61%
1 week+4.17%
Current month+47.25%
1 month+40.27%
3 months-11.28%
6 months-15.79%
Current year-27.14%
1 week 5.06
Extreme 5.0595
5.9
1 month 3.43
Extreme 3.43
5.9
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
44.98
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/6/26 Sell

Chief Financial Officer

-4,089 0.0066%
22/6/26 Sell

Chief Executive Officer

-20,871 0.0339%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%+4.17%+7.14%-37.85% 504M
-3.42%+10.05%+58.59%+87.70% 57.82B
-0.05%-5.85%+54.36%+71.44% 53.71B
-2.71%-9.82%+1.97%+415.22% 23.8B
-1.26%-1.54%-18.61%-14.61% 23.26B
-0.56%+10.26%+44.03%-3.86% 20.7B
-0.29%-2.05%+34.41%-29.62% 17.81B
-4.55%-8.65%+194.32%+349.58% 16.9B
-2.61%+8.99%+46.11%+691.67% 16.36B
-0.15%-2.85%+23.79%+189.06% 13.96B
Average -1.62%+2.23%+44.61%+171.87% 24.48B
Weighted average by Cap. -1.76%+0.21%+48.28%+153.93%

Financials

2026 *2027 *
Net sales 102M 89.05M 82.35M 75.57M 143M 9.82B 146M 982M 386M 4.79B 383M 374M 16.55B 178M 156M 144M 132M 250M 17.19B 255M 1.72B 675M 8.39B 670M 655M 28.97B
Net income -166M -145M -134M -123M -232M -15.95B -236M -1.6B -627M -7.79B -622M -608M -26.89B -142M -124M -115M -105M -199M -13.69B -203M -1.37B -538M -6.68B -534M -522M -23.08B
Net Debt -165M -144M -133M -122M -232M -15.9B -236M -1.59B -625M -7.76B -620M -606M -26.81B -210M -183M -169M -155M -294M -20.2B -299M -2.02B -794M -9.86B -787M -770M -34.05B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
17/07/26 USD 5.625 -1.83% 1,237,005
15/07/26 USD 5.730 +2.87% 2,083,595
14/07/26 USD 5.570 +3.72% 3,004,355
13/07/26 USD 5.370 -2.89% 2,417,232
10/07/26 USD 5.530 +2.41% 2,989,325
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.730USD
Average target price
15.00USD
Spread / Average Target
+161.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock